Klaus Schollmeier
Director/Board Member at CUREVAC N.V.
Net worth: 11 624 $ as of 30/04/2024
Klaus Schollmeier active positions
Companies | Position | Start | End |
---|---|---|---|
CUREVAC N.V. | Director/Board Member | 22/06/2022 | - |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | Chairman | - | - |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Chairman | - | - |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Chairman | 05/11/2020 | - |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Chairman | - | - |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Director/Board Member | - | - |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Chairman | 01/11/2015 | - |
Career history of Klaus Schollmeier
Former positions of Klaus Schollmeier
Companies | Position | Start | End |
---|---|---|---|
ING BHF-Bank AG | Corporate Officer/Principal | - | 06/12/2018 |
SuppreMol GmbH
SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Chief Executive Officer | 01/04/2013 | 01/01/2015 |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░ ░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Klaus Schollmeier
Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Statistics
International
Germany | 10 |
Switzerland | 4 |
Netherlands | 3 |
Operational
Chairman | 6 |
Corporate Officer/Principal | 5 |
Director/Board Member | 3 |
Sectoral
Health Technology | 12 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
CUREVAC N.V. | Health Technology |
Private companies | 13 |
---|---|
BASF Bioresearch Corp. | |
BASF Pharma | |
SuppreMol GmbH
SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Health Technology |
Abbott GmbH (Germany)
Abbott GmbH (Germany) Pharmaceuticals: MajorHealth Technology Abbott GmbH & Co. KG develops and manufactures health care products. It is engaged in the discovery, development, manufacture, and marketing of pharmaceutical, diagnostic, nutritional, and hospital products. It offers pharmaceutical and diagnostic products ranging from prevention and diagnosis to treatment and cure. The company is headquartered in Ludwigshafen, Germany. | Health Technology |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | Health Technology |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Health Technology |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Health Technology |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |
Modra Pharmaceuticals BV
Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
ING BHF-Bank AG | Finance |
- Stock Market
- Insiders
- Klaus Schollmeier
- Experience